PMC10259290_01
Treatment response with decitabine. (A) Trans-axial gallium dotatate PET/CT demonstrating large pancreatic head neuroendocrine tumor (4 x 4.6 cm) with metastatic disease. (B) Saggital gallium dotatate PET/CT scan demonstrating metastatic L2 lesion, compatible with osseous metastatic disease. (C) Trans-axial gallium dotatate PET/CT demonstrating interval decrease in the size of pancreatic head mass 3.8 x 3.2 cm. (D) Sagittal gallium dotatate PET/CT scan demonstrating unchanged L2 lesion, compatible with stable to improved osseous metastatic disease.
EO-22-0052fig1.jpg
PMC10259290_01_EO-22-0052fig1.jpg
fig1
A gallium dotatate PET/CT showed somatostatin receptor avid primary pancreatic malignancy with mesenteric lymphadenopathy and multiple areas of osseous metastatic disease including manubrium and L2 vertebral body (Fig. 1).